C lozapin e (C lozaril) is a uniqu e ant ipsychotic whi ch has bee n shown to be effec t ive in th e treatm ent of refract or y sc hizo phe nia ( 1,2). Com pa red with standard neuroleptics clo zapin e has minimal ext ra pyra m idal side effec ts a nd poses a low risk fo r tardive dysk inesia ( 1, 3, 4, 5, 6) .
Deve lop ed in 1960, clozapine wa s del ayed from earl ie r wid esp read use by it s side effec t profile. The most dangerous of th e co m mo n side effects is agranu locytosis , which has been re po rted in I% to 2% of cas es (7) . Other adverse effe cts incl ude hypot ension, fatigu e, dru g fever, pharmacogenic d elirium, tach ycardia, a nd seizu res . Associat ed se izu re s hav e be en found in 4% of U.S . cases (7) co m pa red to I% to 2% in standard neurolept ics (8) . Data from th e manufacturer, Sandoz, indicat es t ha t t hes e seizures are dos e dependen t with patients treat ed with 600 to 900 mg /day having a se izu re fr equ ency of 5%; those treat ed with 300 to 599 mg /day, 3-4%; a nd those patients treated with less than 300 mg /day having a se izu re fr equ ency of 1-2% (9) . A sim ilar dos e de pen d en t fr equ e ncy was found by Devinsky e t a I, who also sugges t t hat rapid upward t itrat ion of cloz apin e may incr ease se izu re risk ( 10) .
EEG abnorm a liti es have been not ed in 72% of pati ent s on clozapine (II) . T he EEG typicall y shows slow wav es a nd paroxysmal d isch a rg es whi ch m ay ap pear to be e pile p tifo r m. As clozapine us e in cr eases, th e issue of how to m an age clozapineinduced seizures and EEG cha nges becom es a n import ant clinica l pro ble m .
In t his report we pres ent th e case of a pat ient who had a se izu re while o n a low do se of clozapine and an abnormal EEG wh ich persist ed for week s a fter he r last seizure. This is follow ed by a discu ssion of th e uniqu e pr op erti es of clozapine whi ch 36 m ay con t ribu te to it s incr eased seizure fr equ en cy, it s effect o n EEG 's, and a review of cu r re n t gu ide lines in th e clinical m an a gem ent of clozapine-induced seizures .
CASE REPORT
Ms. B. is a 64 year old whit e femal e, gro u p hom e reside n t, with no m edi cal pr obl ems who has a 40 year hist ory of chro nic undi fferent iat ed sch izophreni a. H er psych osis and disorgani zed beh avior had been re fractory to e lectroconvu lsive th erapy a nd trials of multiple neuroleptics. The pati ent was most recently on haloperidol a nd lithium wh en she d evelop ed a se ve re dyst oni c reacti on. Th ese med icat ions were di scontinued and treatment wit h clo za pine was initiat ed as a n ou tpa tient. An initial dose of 25 m g /d ay was incr eased 25 mg eve ry two days. O n day 14 of clozapine treatm ent, a t a dos e of 175 m g/day, t he patient had a wit nessed gen eralized tonic-clonic se izu re. At this tim e she fell to th e floor , had clo nic move me n ts of all ex t re m it ies lasting a ppro ximately tw o minut es th en becam e flaccid an d unrespo nsive for a no t he r two minut es. Upon regaining consc ious ness she ex pe rie nced a one hour period of co nfusion and di sori ent ation . The pati ent had no histo ry of seizures , head trauma , or subst a nce abuse . She had no kn own me dical condi tio ns or recent m ed ication cha nges other th en sta r t ing cloza pine which put he r a t increased risk for a se izure. TO additio nal ge neralize d se izures we re no t ed. Th e group hom e treatm ent tea m did not see k imm edi at e m edi cal cons ultatio n a nd cont in ued cloz apin e treatm ent a t a dose of 175 mg /day. H e r beh avior remained d isorganized for seven days afte r th e se izu re and she was admi tted to t he psychi atric hospital for eva lua t ion of he r prol on ged change in ment al stat us.
Ne u ro log ic ex a m reveal ed psych o mo tor re tarda t ion and confusion without focal se nso ry or mot or findin gs a nd th e re m ai nd er of t he ph ysical exam was unrem arkabl e. M et abolic, toxicology, e ndoc rine, in fecti ou s a nd he m a tological sc ree ns as well as a head CT we re unrem arkabl e. Ini ti al EEG ob tai ne d nine days after th e witnessed se izu re, wit h th e patient st ill o n clozapine, sho wed bet a r hythms in t he ba ckground secondary to treatm ent with benzodi a zepines a nd bri ef runs of diffuse high voltage slow a nd shar p wav e paroxysm al di sch arges as shown in Figure I .
Du e to co nce rn a bou t her prolon ged e nce p ha lopa t hy clozapine was discontinu ed a nd th e patient was sta r te d on ca rba maze pine. The a u t hors were called in for neurological consulta tio n a t this tim e. Follow-up EEG 15 days a fter sto pping th e clozapin e showed resolution of epile pt ifor m activity.
DISC USSION

Dopamine Receptors and Clozapine Action
A g reat deal of inform ation a bo u t dop amine receptor subtypes has recent ly becom e ava ila ble whi ch sho uld she d light on clozapine 's a n tipsy chotic and proconvu lsa n t effec ts. Dop amine rece p to rs are glycopro te in molecul es, locat ed on pr e-synaptic a nd post-synaptic m embra nes a nd fou nd primarily in th e st ria tum , cort ex and limbic FIGURE 1. reveals beta rhythms in the background and f r eq uen t pa roxys ma l bursts of slow and s h a r p wa ve discharges. sys te m . Until recently, dopamin e receptors have been ca tegorize d int o D 1 and D 2 subty pe s. D 1 receptors are t he m ost a bu ndan t d op aminergic rece ptors in t he human brain. They are found in both striatal and cor t ico-lim bic a reas, a nd t hey activat e ade nyla te cyclase and cyclic AMP. D 2 recep to rs a re found in greates t conc en trat ion in th e st ria t um and were t ho ug h t to inhibit cyclic AMP. Ne u ro le p tic pot ency has been rat ed by th e dose requ ir ed to anta gonize th e D 2 receptor. Advances in molecular biology have led to the cloning of genes for 2 typ es of D, a nd D 2 recept ors ( 12, 13) and th e dis covery of D 3 , D 4 and D, re ceptors (14 ,15) . Th e D 3 _ S recept or s a ppear to be localized primarily outside th e striatum in cor t ica l a nd limbic region s.
The me chanism of clozapine's clinical antipsychotic efficacy has prompted a great deal of investigation. Th e neuropharmacology of clozapine was rec ently reviewed by Baldes sarini and Frankenberg (16) and M eltzer (17) . C loza pine is a weak antagonist a t th e dopamine D 1 and D 2 rec eptors and moderat e an tagonist of 5HT2, 5H T3, alpha I, alpha 2 and bet a-adren ergic receptors and exhi bits a n tic ho linergic and antihistiminic properties . Recent work ha s pointed to D 4 and D 3 a n tagonism as th e possible m edi ator of th e antipsychotic ac t ivity of clozapine (14, 15) . Ne urophysiologi c studies of clozapine indicate a pr eferential effec t on th e A I0 neu ron s pr oj ect ing to limbic areas and minimal affect on th e A9 neurons pr ojecting in to th e bas al ganglia (18) . The D 4 rec eptor appears to be loca t ed primarily o utside t he striatum which co uld explain clozapine 's lack of significant ex t ra pyram ida l effec ts .
Dopamine and Se iz ures
H ow dopamine antagonists induce seizures is not well underst ood . Som e eVIdence points to dopamine as a regulator of se izu re acti vit y (19) . Th e specifi c ro le whi ch each dopamine receptor plays has ye t to be full y resolved. Loscher and C zu czwar and Turski e t al found that D 2 agonist s su ch as L-D op a a nd th e mixed D b D 2 agonist apomorphine had an anticonvulsant effec t whil e D 2 a n tagonists, like clozapine, t end to lower th e seizure threshold (19 ,20 ,21 ,22) . These da t a suggest that clozapine's blockade of D 2 receptors is responsibl e for its associa te d se izu res but th is do es not expla in th e in cr eased preval en ce of clozapine rel at ed se iz ures co mpared to st and ard neuroleptics. Burke e t al demonstrated th e opposit e effec t with D, re ceptor com pou nds (19) . In his study in mi ce, D, agonist s lower th e se izu re threshold to pilocarpine and picrotoxin and D 1 ant agonists ex ert ed a prot ecti ve effect agai nst seizures. An additional m echanism is suggest ed by Giardino e t al who repor t ed a de cr ease in benzodiazepine re ceptor density in rat co r te x a fte r chro nic clozapin e administration (23) , raising th e possibility that clo zapine cou ld alt er t he seizure threshold throughits effec ts on GABA-ergic syst ems.
EEG Changes Du ring Cloeapine Treatment
The patient described in this report had epil eptiform dis ch arges on her EEG following administration of clozapine. Re cent studies su ggest th at most pa ti ents receiving clozapine have abnormal EEGs (11 ,24,2 5) . Th ese cha nges have be en report ed to be dos e related (26) but cha nges have been not ed a fte r a sin gle dose (27) . Tiihonen e t al found that 16 of 16 subjects studied had profound di sturban ces of background activity and also paroxysms consist ing of d elt a a nd th et a waves, sev en patients had paroxysms which were classified as epile pt ifor m, cons ist ing of sp ikes, pol yspikes , or spikes and slow wave co m plexe s (24) . Thes e findin gs corre la te with an ea rlie r study by Isermann and Haupt who found 26 of 36 subjects st udi ed had abnormal EEGs aft er beginning clozapine (II) . Fifteen had paroxysm al e pisodes of generalized slowing and 8 had e pile p t ifor m dis charges . Koukkou also suggest ed t ha t clozapine-induced EEG cha nges a re associat ed with a better resp on se to clozapine than those patients whose EEGs remain normal (25) .
Management ofClozapine-Induced S eizures
W e present this case since th e managem ent of this pati ent bro ug ht ou t a number of important points concerning clozapine-induced se izu res . Th e g ro up ho me treatment team was unfamiliar with th e managem ent of cloz apin e-indu ced se izu res as evide nc ed by th e continuation of the clozapine a t th e sam e do se a fte r t he se izure and the seven day delay in obt aining a m edical eva lua tio n.
Several recent papers comment on the managem ent of cloz a pine-r elat ed se izures (7, 10,16 ,28,29,30) . Prevention of seizures ca n be e nha nced by: I) no t exceeding dos es of 600 mg/day; 2) slowly increasing daily dos es; and 3) avoidi ng conco m itan t us e of other medications whi ch also lower th e seizure threshold . For exa m ple, lithium, neurol eptics and tricyclic antidepressants ca n lower th e seiz ure th reshold .
It is not known if pre-existing subclinica l EEG a bnor malit ies incr ease a patien t 's risk for seizures while on clozapine but at pr esent , we do not recomme nd a n EEG for all patients prior to beginning cloz apin e treatm ent. Pati ents with a hist ory of se izu res and /or confusional sta tes should have a ba selin e EEG before star t ing clozapine. An EEG sho uld also be performed on patients who have a cha nge in m e nt al stat us o r seizure while on cloz apine. In th e case d escribed this ste p sh ould have been ta ken imm ediately aft er th e patient had the seizure.
Subclinical EEG cha nges in the a bse nce of associated clin ica l findi ngs do not necessarily require a n alt eration in clo zapine treatment. Cl ozapine-rel at ed se izures are not a n absolut e indication for dis continuation of th erapy bu t ce r tain ste ps, wh ich were not follow ed in th e cas e described , should be taken imm ediat ely a ft er suc h a n eve nt. Other possibl e causes of seizure should be investigat ed . This work-up sho uld includ e EEG, head CT, laboratory eva lua tio n and possibl y a neurological consultation. Following a seizure, clozapine should be held until th e pati ent 's ment al sta te returns to baseline and th en th e daily dos e of cloz apin e should be reduced . Liebe rman e t al suggest a 50% reduction in th e daily dos e (7). The m anufactu re r st a te s t ha t 31 of th e 41 cases in whi ch seizures developed remained on cloz apine d espit e se izures . Less than 5% have had a second seizure with simultaneou s treatm ent with valp ro ic acid (data on file, Sandoz Pharmaceuticals, 1991) . In th e case pr esent ed cloza pine had not yet d emonstrated an antipsychotic effec t and th e t reatment team decided to dis continue her cloz apin e and us e ca rba m a ze pine t empor arily to stabilize he r m ental state .
A la ck of consensus exists conce r ning th e conco m ita n t use of a n t icon vu lsa nts after a clozapine-induced seizure. If a clinician decid es to use a n a nt iconvulsa n t, valproic acid is th e drug of choice as ph en ytoin may ca use a decr ease in clozapine plasma levels (31) and ca rba m a ze pine should be avoide d du e to th e possib ility of depress ed granulocyt e produ ction. One d eath has been rep ort ed in a pa tien t on
